Results 81 to 90 of about 23,609 (230)
MedComm – Oncology, Volume 4, Issue 3, September 2025.TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi +5 more
wiley +1 more source
Extramedullary myeloid tumors in primary myelofibrosis [PDF]
, 1965 Philip Lieberman +2 more
openalex +1 more source
Ruxolitinib for Myelofibrosis [PDF]
New England Journal of Medicine, 2012 Steffen, Koschmieder +2 more
openaire +4 more sources
Effects of Splenectomy on Red-cell Production in Myelofibrosis [PDF]
, 1961 G. Wetherley‐Mein +2 more
openalex +1 more source
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology, Volume 19, Issue 8, Page 2174-2195, August 2025.In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature
Cancer Reports, Volume 8, Issue 8, August 2025.ABSTRACT Background Hydroxyurea (HU) is an antimetabolite used to treat different myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia (ET). HU has a significant effect on the treatment of myeloproliferative disease. Recent Findings A 54‐year‐old woman with a history of ET from 15 years ago
Safoura Shakoei, Zahra Nilfroushan
wiley +1 more source
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +1 more source
Primary and Secondary Myelofibrosis: Its Relationship to "PNH-like Defect" [PDF]
, 1972 Chi-yen Kuo +2 more
openalex +1 more source
International Journal of Cancer, Volume 157, Issue 3, Page 526-533, 1 August 2025.What's new? Current treatment goals for polycythemia vera, a myeloproliferative neoplasm characterized by JAK2 mutations, are mainly to prevent thrombosis. While ropeginterferon alfa‐2b treatment also reduces JAK2 mutation burden, the correlation between the hematologic and molecular responses remains to be clarified.
Seug Yun Yoon +15 more
wiley +1 more source
Acute massive myelofibrosis with acutelymphoblastic leukemia
Turkish Journal of Hematology, 2009 Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Namık Özbek +5 more
doaj